Cargando…

Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy

AIMS: Glucagon‐like peptide 1 (GLP-1) receptor agonists have demonstrated strong glycemic control. However, few studies have investigated the effects of switching from insulin to GLP-1 receptor agonists. We aimed to investigate, using real-world data, whether switching to dulaglutide improves glycem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Youngsook, Huh, Ji Hye, Lee, Minyoung, Kang, Eun Seok, Cha, Bong-Soo, Lee, Byung-Wan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248324/ https://www.ncbi.nlm.nih.gov/pubmed/35784534 http://dx.doi.org/10.3389/fendo.2022.880164

Ejemplares similares

Impaired ketogenesis is associated with metabolic-associated fatty liver disease in subjects with type 2 diabetes
por: Lee, Sejeong, et al.
Publicado: (2023)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2020)

Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes
por: Huang, Jinxin, et al.
Publicado: (2023)

Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2018)

Characteristics Predictive for a Successful Switch from Insulin Analogue Therapy to Oral Hypoglycemic Agents in Patients with Type 2 Diabetes
por: Kim, Gyuri, et al.
Publicado: (2016)

The Relationship between BMI and Glycated Albumin to Glycated Hemoglobin (GA/A1c) Ratio According to Glucose Tolerance Status
por: Huh, Ji Hye, et al.
Publicado: (2014)

Relationship Between Circulating Netrin-1 Concentration, Impaired Fasting Glucose, and Newly Diagnosed Type 2 Diabetes
por: Yim, Jisook, et al.
Publicado: (2018)

Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes
por: Su, Yu, et al.
Publicado: (2023)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

1,5-Anhydroglucitol as a Useful Marker for Assessing Short-Term Glycemic Excursions in Type 1 Diabetes
por: Seok, Hannah, et al.
Publicado: (2015)

Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus
por: Kim, Hae Kyung, et al.
Publicado: (2022)

Uric Acid Variability as a Predictive Marker of Newly Developed Cardiovascular Events in Type 2 Diabetes
por: Kim, Hae Kyung, et al.
Publicado: (2021)

Protective Effect of Delta-Like 1 Homolog Against Muscular Atrophy in a Mouse Model
por: Lee, Ji Young, et al.
Publicado: (2022)

A Case of Dulaglutide-Induced Vaginal Bleed
por: Vaccaro, Christopher J, et al.
Publicado: (2023)

Pre-sarcopenia is associated with renal hyperfiltration independent of obesity or insulin resistance: Nationwide Surveys (KNHANES 2008–2011)
por: Han, Eugene, et al.
Publicado: (2017)

Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
por: Kim, Hyun Min, et al.
Publicado: (2015)

Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study
por: Kim, Hwi Seung, et al.
Publicado: (2022)

Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus
por: Choe, Eun Yeong, et al.
Publicado: (2012)

Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
por: Bae, Jaehyun, et al.
Publicado: (2022)

The effects of the voglibose on non-alcoholic fatty liver disease in mice model
por: Bae, Jaehyun, et al.
Publicado: (2022)

Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors
por: Lee, Ji-Yeon, et al.
Publicado: (2019)

Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report
por: Dardano, Angela, et al.
Publicado: (2022)

Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway
por: Lee, Ji-Yeon, et al.
Publicado: (2021)

Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report
por: Khan, Abu baker, et al.
Publicado: (2023)

Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression
por: Lee, Minyoung, et al.
Publicado: (2020)

Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes
por: Song, Sun Ok, et al.
Publicado: (2013)

Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus
por: Du, Juan, et al.
Publicado: (2023)

Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study
por: Sanada, Junpei, et al.
Publicado: (2021)

Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and β-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis
por: Bae, Jaehyun, et al.
Publicado: (2018)

Case Report of Acute Pancreatitis Associated With Combination Treatment of Dulaglutide and Glipizide
por: Babajide, Oyedotun, et al.
Publicado: (2022)

Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)
por: Cho, Yongin, et al.
Publicado: (2022)

First Reported Case of Dulaglutide-Induced Acute Pancreatitis With Normal Serum Lipase Level
por: Shahbazi, Mohammad, et al.
Publicado: (2023)

Inadequate detection of the FSHR complicates future research on extragonadal FSHR localization
por: Tedjawirja, Victoria N., et al.
Publicado: (2023)

Effects of Serum Albumin, Calcium Levels, Cancer Stage and Performance Status on Weight Loss in Parathyroid Hormone-Related Peptide Positive or Negative Patients with Cancer
por: Lee, Ji-Yeon, et al.
Publicado: (2018)

Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus
por: Lee, Hokyou, et al.
Publicado: (2020)

Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo‐controlled, double‐blind, multicenter trial
por: Lu, Chieh‐Hsiang, et al.
Publicado: (2015)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

The Optimized Calculation Method for Insulin Dosage in an Insulin Tolerance Test (ITT): A Randomized Parallel Control Study
por: Zhang, Yuwen, et al.
Publicado: (2020)

Inverse Association between Glycated Albumin and Insulin Secretory Function May Explain Higher Levels of Glycated Albumin in Subjects with Longer Duration of Diabetes
por: Lee, Yong-ho, et al.
Publicado: (2014)

Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study
por: Lee, Hyeok-Hee, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cl4ntt2untcc2sbhs52tusp6nb